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Abstract 
Background: 
Embolic strokes of undetermined source (ESUS) comprise up to 20% of ischemic 
strokes. The stroke recurrence rate is substantial with aspirin, widely used for secondary 
prevention. The NAVIGATE ESUS international trial will compare the efficacy and 
safety of rivaroxaban, an oral factor Xa inhibitor, versus aspirin for secondary prevention 
in patients with recent ESUS. 
Main hypothesis: 
In patients with recent ESUS, rivaroxaban 15mg once daily will reduce the risk of 
recurrent stroke (both ischemic and hemorrhagic) and systemic embolism (primary 
efficacy outcome) compared with aspirin 100mg once daily. 
Design: 
Double-blind, randomized trial in patients with ESUS, defined as non-lacunar 
cryptogenic ischemic stroke, enrolled between 7 days and 6 months from the qualifying 
stroke. The planned sample size of 7000 participants will be recruited from 
approximately 480 sites in 31 countries between 2014 and 2017 and followed for a mean 
of about two years until at least 450 primary efficacy outcome events have occurred. The 
primary safety outcome is major bleeding. Two substudies assess (1) the relative effect of 
treatments on MRI-determined covert brain infarcts and (2) the biological underpinnings 
of ESUS using genomic and biomarker approaches.  
Summary: 
The NAVIGATE ESUS trial is evaluating the benefits and risks of rivaroxaban for 
secondary stroke prevention in ESUS patients.  Main results are anticipated in 2018.
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Introduction: 
Ischemic strokes traditionally classified as cryptogenic remain frequent despite advances 
in the diagnostic techniques to determine stroke etiology.(1,2) Most non-lacunar 
cryptogenic ischemic strokes are presumed due to emboli, originating from a multitude of 
cardiac and arterial sources or occasionally from venous thromboembolism (i.e. via 
paradoxical embolism).(1)  Cryptogenic conventionally denotes a stroke where high-risk 
sources of embolism (such as atrial fibrillation) are absent, but many patients diagnosed 
with cryptogenic stroke are found to have one or more potential embolic sources if 
thoroughly evaluated, and it is often not possible to be certain of the specific origin of the 
suspected embolus.(3,4) These observations have led to the construct of embolic strokes 
of undetermined source (ESUS) in order to define a cohort of patients that may respond 
better to anticoagulation than antiplatelet therapy for secondary stroke prevention.(1) In 
brief, ESUS is diagnosed when a non-lacunar ischemic stroke occurs in a patient in 
whom subsequent investigations do not show another specifically treatable underlying 
stroke etiology, primarily >50% stenosis in a proximal extracranial or intracranial artery, 
atrial fibrillation or other major-risk cardioembolic source.  A recent prospective global 
registry reported that 16% of ischemic stroke patients met criteria for ESUS (19% if 
stroke patients who did not undergo the complete evaluation required for diagnosis were 
excluded).(5) 
 
Supported by their efficacy for prevention of embolic stroke in atrial fibrillation 
patients,(6,7) anticoagulants have been hypothesized to be more efficacious than 
antiplatelet drugs for secondary prevention following ESUS.(1) The most promising 
anticoagulants for the prevention of embolic stroke and systemic embolism are the non-
vitamin K antagonist direct oral anticoagulants (DOACs). Compared with warfarin and 
its congeners, DOACs carry a lower risk of intracranial hemorrhage, the most devastating 
complication of anticoagulation.(8) The ESUS construct combined with the availability 
of efficacious and safe DOACs have prompted the initiation of several randomized trials 
aimed at reducing recurrent stroke in ESUS patients.(9-11)  Here, the design highlights 
and key protocol issues of the New Approach riVaroxaban Inhibition of Factor Xa in a 
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Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined 
Source (NAVIGATE ESUS) trial are presented. 
 
Design 
Overview and timelines 
NAVIGATE ESUS (Clinicaltrials.gov.NCT02313909) is an international, double-blinded, 
randomized phase III trial comparing rivaroxaban 15 mg once daily (immediate-release, 
film-coated tablets) with aspirin (enteric-coated) 100 mg once daily, both to be taken with 
food, in patients with recent ESUS.(Figure 1) Matching placebos will be used in this 
double blinded trial. The primary hypothesis is that rivaroxaban is superior to aspirin for 
reducing the risk of recurrent stroke and systemic embolism (primary efficacy outcome). 
Seven thousand patients will be enrolled to detect a >30% reduction in primary efficacy 
outcome events with 90% power by assignment to rivaroxaban based on an estimated rate 
of 3.8% per year among aspirin-assigned patients.(1) Participants will be randomized 
between 7 days and six months following the qualifying ESUS at about 480 sites in 31 
countries.(Figure 2)  Patient recruitment began in December 2014 and is anticipated to 
finish in 2017.  Mean patient follow-up is expected to be about two years, but the study 
will continue until at least 450 participants have experienced a primary efficacy outcome 
event. The main results are anticipated to be available in 2018. 
 
Study population 
Screening ischemic stroke patients for participation is based on five key eligibility criteria 
as summarized in Table 1. In short, patients >50 years old with non-lacunar ischemic 
stroke visualized by neuroimaging and without a clear etiology are included for whom 
most current guidelines recommend antiplatelet therapy for secondary prevention.(Figure 
3) After the qualifying stroke, at least 20 hours of cardiac rhythm monitoring is required 
to exclude atrial fibrillation lasting >6 minutes, although investigators can choose to 
monitor for longer periods per local clinical practice standards. Intracranial arterial 
imaging is not required, but if done, the presence of >50% intracranial atherosclerotic 
stenosis supplying the ischemic area excludes participation.  Patients with left ventricular 
systolic dysfunction of any severity, patent foramen ovale (PFO), and all types of aortic 
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arch plaque are eligible if anticoagulation (or PFO closure) is not planned and potential 
randomization to aspirin is acceptable to local investigators. Transthoracic 
echocardiography is mandatory, with transesophageal echocardiography optional and an 
acceptable substitute, with intracardiac thrombus detected by either technique an 
exclusion criterion. Patients with carotid artery atherosclerotic plaques causing <50% 
stenosis are eligible regardless of ulceration or other features. The outer time limit (i.e six 
months) between qualifying stroke and randomization was chosen because the temporal 
pattern of recurrent stroke is not known for ESUS patients and it was deemed worthwhile 
to determine the absolute benefits of anticoagulation for ESUS patients who are identified 
after the acute phase due to diagnostic delays.  
 
Exclusion criteria include severely disabling stroke (modified Rankin score ≥4 at 
screening), the presence or plan to insert an implantable ECG loop recorder, specific 
indication for chronic anticoagulation or for chronic antiplatelet therapy, ongoing regular 
use of conventional non-steroidal anti-inflammatory drugs, previous non-traumatic 
intracranial hemorrhage (an exception is hemorrhagic transformation of ischemic stroke), 
and required use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) 
and P-glycoprotein (e.g. protease inhibitors and several azole-antimycotic agents).(Table 
2) 
 
Patients are randomly allocated by an interactive voice/web response system to either 
rivaroxaban or aspirin in a 1:1 ratio, with the block size sequestered until the end of 
recruitment. Randomization is stratified by country and by age <60 and ≥60 years.  
 
Follow-up 
Participants return for outpatient office visits at one, six, and 12 months and then every 
six months until a common end-study date. At three months, participants are contacted by 
telephone, and a telephone contact is done one month after the end-of-treatment visit. 
Participants are assessed for the occurrence of safety and efficacy events, adherence, 
adverse events and vital signs, and quality of life, functional status and cognitive function 
are recorded. Adherence to assigned therapy is assessed by interview and pill counts at 
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each visit. Low-dose (<100 mg daily) aspirin in addition to study-assigned therapy is 
permitted if a new indication develops during follow-up (e.g. stable coronary artery 
disease), but dual antiplatelet therapy mandates cessation of study drug for the duration of 
use. 
 
Outcome events 
The primary efficacy outcome is time to recurrent stroke (ischemic, hemorrhagic and 
undefined stroke, including TIAs with positive neuroimaging) or systemic embolism. 
This outcome was chosen in part to align with trials demonstrating a substantial reduction 
in the risk of embolic events by DOACs in atrial fibrillation patients. Secondary efficacy 
outcomes are outlined in Table 3. The primary safety outcome is major bleeding 
according to the criteria of the International Society of Thrombosis and Haemostasis.(12)  
We anticipate that the annual rate of intracerebral hemorrhage will be relatively low 
(<0.4%/yr) due to prohibition of concomitant dual antiplatelet therapy, exclusion of 
lacunar strokes as qualifying events, and delayed initiation of anticoagulation for a least 
seven days after the qualifying stroke, and be equal in both treatment arms.  Extracranial 
major hemorrhage is anticipated to be increased among those assigned rivaroxaban 
versus aspirin (2%/year versus 1%/year, respectively).(13,14) 
 
Statistical analysis plan 
The primary efficacy analyses will be based on the intent-to-treat population. 
Rivaroxaban-assigned patients will be compared with the aspirin control group using a 
log-rank test.  Kaplan-Meier estimates will be used to plot the cumulative incidence risk 
over time.  Risk reduction will be estimated with the Cox proportional hazards model.  
Secondary efficacy outcomes will be analyzed using similar methods as for the primary 
efficacy analysis, with testing performed in hierarchical order to control the global type 1 
error level.(Table 3) The statistical analysis plan includes several prespecified subgroup 
analyses based age, sex, global region, and time from index stroke to randomization of 
<30 days, 31 days to 3 months, and >3 months. 
 
Study development and committees 
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The trial co-principal investigators from the Population Health Research Institute (RGH, 
SJC) initially proposed the trial to Bayer Pharma AG (SDB). The Steering Committee is 
responsible for the scientific leadership and consists of the national leaders (n=32) of 
each participating country, the co-principal investigators, sponsor representatives, and 
additional experts in thrombosis and clinical trials. The Publications Committee approves 
all manuscripts prior to submission and consists of four national leaders (rotating 
annually), the co-principal investigators, and a sponsor representative. Sponsor 
representatives (who comprise <15% of these two committees) have voting rights. 
Outcome event verification is overseen by a central Adjudication Committee that will 
assess whether reported outcome events meet study criteria. 
 
An independent Data Monitoring Committee monitors participant safety on an ongoing 
basis and may recommend modification of the study protocol in case unexpected safety 
concerns arise or may terminate the study for safety concerns that are not offset by 
benefits related to stroke reduction. Two formal interim analyses will occur when 
approximately 50% and 67% of primary efficacy outcome events have accrued, and the 
trial will be stopped for overwhelming efficacy by one treatment relative to another if not 
mitigated by safety issues. 
 
Two substudies 
The primary objective of the MIND MRI Substudy is to determine the effect of 
rivaroxaban versus aspirin on MRI-defined clinically silent (or covert) brain infarcts and 
clinical ischemic strokes. Covert infarcts are neither asymptomatic nor benign and result 
in considerable morbidity including cognitive decline, loss of independence, gait 
impairment and falls. While stroke recurrence increases the likelihood of dementia, post-
stroke cognitive decline often occurs in the absence of clinical recurrence. The 
mechanism is thought to be either a manifestation of the increasing vascular burden or an 
interaction between subclinical ischemia and coexisting neurodegenerative pathology, 
principally Alzheimer’s disease. Therapies aimed at interrupting the accumulating 
vascular pathology and its consequences may improve the cognitive and functional 
trajectory of ESUS patients. 
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The incidence of covert brain infarcts is expected to exceed recurrent clinical ischemic 
strokes, but owing to the possible heterogeneous pathogenesis of these lesions, covert 
infarcts may be less sensitive to anticoagulants regarding prevention. About 1000 
participants will undergo brain MRI using a standardized acquisition protocol near the 
time of randomization that will be repeated near study end.  MRIs will be interpreted at a 
core MRI facility by experts unaware of treatment assignment.  
 
The Biomarker, Genetics, Gene Expression Substudy will collect plasma, RNA and DNA 
samples from up to 3000 participants for exploratory analyses aimed at establishing 
whether ESUS is a distinct clinical entity or the result of multiple unrelated causes that 
have in common a propensity for thrombosis.. The substudy will integrate biomarker 
information, comprehensive genomics characterization and gene expression (including 
miRNA) data to identify pathways linked to ESUS and stroke recurrence. Integration of 
these approaches has the potential to be more revealing than the use of any one alone.   
Anticipated analyses include the predictive value of D-dimer for recurrent stroke, NT-
proBNP levels as predicting atrial fibrillation during follow-up, and several as yet 
undefined, exploratory biomarkers for predicting clinical events. 
 
Design issues 
Choice of aspirin as the control antiplatelet therapy 
Aspirin is the best characterized and most widely-used antiplatelet therapy for secondary 
stroke prevention. Most experts believe that there is no compelling evidence that other 
antiplatelet agents offer important benefits over aspirin, and hence many major guidelines 
include aspirin as acceptable chronic antiplatelet therapy for secondary stroke prevention, 
including for patients with cryptogenic ischemic strokes.(15-17) However, in some 
countries, aspirin monotherapy is not the preferred antiplatelet therapy for secondary 
stroke prevention.(18) If investigators were allowed to choose the antiplatelet comparator 
and dose based on local preference, a double-blind comparison with rivaroxaban would 
not be feasible, and it was elected to choose a single antiplatelet comparator. For ESUS 
patients, there are no existing data about relative efficacy of different antiplatelet 
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therapies. Hence, aspirin is the most reasonable choice for the antiplatelet control arm of 
NAVIGATE ESUS and in-line with current global practice.(5,18) 
 
Choice of 15 mg once daily dose of rivaroxaban 
The selection of a dose of anticoagulant for a new indication often involves a phase 2 
dose-ranging study. However, such a study was not considered feasible due to the 
relatively low rate of recurrent stroke in ESUS patients and the absence of an established 
surrogate biomarker. Consequently, the dosage was extrapolated from clinical evidence 
on the use of rivaroxaban in other patient populations. Rivaroxaban 20 mg daily (15 mg 
daily for those with an estimated creatinine clearance between 30 and 49 ml/min) was 
efficacious and safe in patients with atrial fibrillation, in whom embolism is the dominant 
cause of stroke.(19) Rivaroxaban 15 mg daily dose appears to be efficacious for stroke 
prevention in Japanese patients with atrial fibrillation.(20)  Due to concern about a 
potentially higher rate of intracerebral hemorrhage in patients with recent ischemic 
stroke, a dosage of 15 mg once daily in ESUS patients, without dose reduction for 
moderate renal impairment, was deemed appropriate. Modelling data show an overlap of 
exposure (i.e. of rivaroxaban plasma concentrations over time) for the 15mg and 20mg 
doses. For this patient population, rivaroxaban 15mg daily was chosen to optimally 
balance efficacy with safety. 
 
Screening participants for covert paroxysmal atrial fibrillation 
When the trial was designed in 2013-2014, the approach to detection of atrial fibrillation 
at many stroke centers was an ECG at hospital admission and 24 hours of inpatient 
telemetry or Holter monitoring.(5,22)  In mid-2014, two influential studies reported that 
brief episodes (several minutes) of previously unrecognized atrial fibrillation could be 
detected in 10-20% of patients with cryptogenic ischemic stroke if the duration of cardiac 
monitoring was prolonged to 30 days.(23,24)  However, it is unknown whether brief (<6 
minutes) episodes of atrial fibrillation detected weeks or months after stroke identify 
patients who benefit from anticoagulation. Further, short episodes of atrial fibrillation are 
not necessarily temporally associated with stroke risk, raising further doubt about their 
relevance to the pathogenesis of stroke.(25) 
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 For NAVIGATE ESUS eligibility, screening for covert paroxysmal atrial fibrillation with 
>20 hours of cardiac rhythm monitoring is required, with episodes >6 minutes duration 
mandating exclusion based on the ASSERT trial.(26) Sites are permitted to monitor for 
longer periods (e.g. 7 to 30 days) based on local clinical practice, but monitoring must be 
completed prior to randomization. Randomization of patients undergoing prolonged (e.g. 
months to years) cardiac rhythm monitoring using implanted recorders is an exclusion 
criterion because of the uncertain implications of subgroup analysis in those with 
implanted monitoring devices and the likelihood of cross-over based on current 
enthusiasm in some countries for the use of anticoagulants if even brief episodes of atrial 
fibrillation are detected.  
 
If NAVIGATE ESUS results demonstrate a reduction in recurrent ischemic stroke with 
anticoagulation, could this overall result be driven by a large treatment effect among a 
subgroup of subjects with covert paroxysmal atrial fibrillation? While this is unlikely 
based on predicted frequencies, this possibility will be assessed by routine clinical 
screening to determine if atrial fibrillation is present at the time of primary efficacy 
events and comparing the frequency of atrial fibrillation between treatment arms. Further, 
if rivaroxaban shows superior efficacy versus aspirin and is relatively safe for ESUS 
patients, it will challenge the need for prolonged cardiac rhythm monitoring for most 
patients with cryptogenic stroke.  
 
Relative effects of rivaroxaban versus aspirin on different embolic sources 
ESUS includes multiple sources (cardiac, arterial, paradoxical). Are different embolic 
sources likely to respond similarly to rivaroxaban versus aspirin? Clinical trials have not 
shown a benefit of anticoagulation over antiplatelet therapy for secondary prevention of 
stroke due to arterial sources (including intracranial stenosis and aortic arch atheroma), 
but subgroup analyses support the biologic plausibility if a consistent anticoagulant effect 
can be maintained.(27-29)  Further, often two or more potential embolic sources are 
detected in individual ESUS patients, and the specific culprit cannot be identified, so that 
it is pragmatic to assess the relative effect of antithrombotic therapies among all ESUS 
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patients. A series of exploratory subgroup analyses will examine recurrent stroke rates 
and response to anticoagulation associated with individual potential embolic sources as 
well as the presence of prothrombotic disorders (e.g. active cancer).(30,31) 
 
Should transesophageal echocardiography (TEE) be required for eligibility? 
Minor-risk embolic sources are more frequently detected using TEE than with precordial 
echocardiography,(32) and TEE is sometimes recommended routinely for young patients 
with cryptogenic stroke.  However, global surveys indicate that TEE is infrequently done 
in routine clinical practice, (5,22) and with uncertain evidence-based management 
implications.(33)  While it would be ideal to more accurately characterize minor-risk 
embolic sources, mandating TEE (mildly invasive and costly) for trial eligibility would 
severely restrict the number of participating sites and bias recruitment to patients willing 
to undergo this procedure.  
 
Discussion 
Although an embolic etiology for most cryptogenic ischemic strokes was proposed more 
than two decades ago,(4) there has been little progress in secondary stroke prevention for 
this large fraction of patients with ischemic stroke. Among such patients meeting criteria 
for ESUS, we anticipate that rivaroxaban will be associated with a reduced risk of 
recurrent embolic events, similar rates of intracranial hemorrhage, and only modestly 
increased (and potentially acceptable) rates of major extracranial hemorrhage relative to 
aspirin. NAVIGATE ESUS is a multinational, randomized, double-blind, superiority trial 
comparing antithrombotic therapies for secondary stroke prevention in a well-defined 
cohort of patients with non-lacunar cryptogenic stroke with embolic features. In order to 
be widely applicable globally, the trial is designed pragmatically (e.g. intracranial 
imaging is not required because this would exclude participation of many sites where this 
is not standard practice, and the duration of cardiac rhythm monitoring over 20 hours is 
flexible). Anticipated subgroup analyses comparing rivaroxaban with aspirin for stroke 
prevention in participants with PFO, left ventricular systolic dysfunction, active cancer, 
or nonstenotic atherosclerotic plaques in the aorta, carotid arteries and intracranial 
arteries are likely to be underpowered, but still of considerable clinical interest. 
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NAVIGATE ESUS is likely to be a landmark clinical trial impacting clinical management 
of large numbers of patients with cryptogenic ischemic stroke attributed to embolism. 
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Table 1. Inclusion criteria  
Embolic stroke of undetermined source (ESUS)* between 7 days** and 6 months: 
1. Ischemic stroke visualized by CT or MRI that is not lacunar† 
2. Absence of extracranial and, if intracranial imaging performed, intracranial 
atherosclerosis causing >50% luminal stenosis of arteries supplying the area of ischemia# 
3. No atrial fibrillation by history, ECG, or after >20 hours of cardiac rhythm monitoring+ 
4. No intracardiac thrombus by echocardiography 
5. No other specific cause of ischemic stroke identified (e.g. high-risk cardiac source^ 
usually requiring anticoagulation, cardiac tumor, arteritis, dissection, migraine/vasospasm, 
cerebral venous thrombosis, drug abuse) 
Age >50 years^^ 
Ability and willingness to provide written informed consent 
CT = computed tomography; MRI = magnetic resonance imaging; ECG = electrocardiogram. 
* Criteria for ESUS contrast with the original definition proposed by the Cryptogenic Stroke / ESUS 
International Working Group in three main ways (1): intracranial arterial imaging is not required, 
intracranial arterial occlusion does not exclude participation if diagnosed as embolic, and exclusion based 
on echocardiography is limited to intracardiac thrombus. 
** Patients with minor stroke (NIH stroke scale score <3) can be entered as soon as 3 days after onset and 
not before 10 days in case of hemorrhagic transformation or  intravenous thrombolysis therapy and no 
repeat CT or MRI performed before randomization documents the absence of new or extension of bleeding.  
†Lacunar defined as an infarct <1.5 cm in largest dimension involving any subcortical area of the cerebral 
hemispheres, pons, and midbrain. 
# Arterial imaging includes sonography (including transcranial Doppler) or CT, MR or digital subtraction 
angiography of the relevant arteries. 
+ Cardiac rhythm monitoring using automated rhythm detection strongly encouraged, but cardiac telemetry 
carried-out in an inpatient stroke unit accepted. 
^ Mechanical prosthetic cardiac valve, atrial myxoma or other cardiac tumors, severe mitral stenosis, or 
infective endocarditis. 
^^ Patients between age 50 and 59 must have one or more additional stroke risk factors (hypertension, 
tobacco smoking at time of qualifying stroke, ischemic stroke or TIA prior to qualifying stroke, heart 
failure, or diabetes); patients age >18 to 50 years with risk factors were eligible prior to the protocol 
amendment of late 2015. 
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Table 2. Key exclusion criteria 
 
 
 
  
 
1. Severely disabling stroke (modified Rankin score ≥4 at screening) 
2. Patent foramen ovale with plans for closure 
3. Known serious infection or inflammatory disease that may be the cause of stroke 
4. Patient has or is intended to receive an implantable ECG loop recorder 
5. Indication for chronic anticoagulation 
6. Indication for chronic antiplatelet therapy  
7.  Active bleeding / major bleeding within last six months / previous nontraumatic 
intracranial hemorrhage (any type, ever) / high risk for serious bleeding 
8.  Hepatic disease associated with coagulopathy 
9. Renal disease with estimated GFR < 30 mL/min/1.73 m2  
10. Life expectancy less than six months 
11. Use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-
glycoprotein (e.g. protease inhibitors and several azole-anti-mycotic agents) 
12. Female of childbearing potential who is not surgically sterile or who is sexually active and 
not using reliable contraception 
13. Chronic, regular use of a conventional non-steroidal anti-inflammatory drug 
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Table 3. Trial outcome events  
        Primary efficacy outcome: 
 Stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive 
neuroimaging) and systemic embolism 
 
 Secondary efficacy outcomes*: 
 Cardiovascular death (including death due to all types of hemorrhage), recurrent 
stroke, systemic embolism, and myocardial infarction 
 All-cause mortality 
 Individual components of the primary and secondary efficacy outcomes (stroke, 
cardiovascular death, and myocardial infarction) as well as  
 Recurrent ischemic stroke (including TIA with positive neuroimaging) 
 Disabling/fatal stroke (modified Rankin score >4) at 90 days after recurrence 
 
Primary safety outcome: 
 Major bleeding meeting ISTH criteria (12) 
 
Secondary safety outcomes: 
•   Life-threatening bleeding 
•   Clinical relevant non-major bleeding 
•   Intracranial hemorrhage 
 
*Listed in the order of sequential testing. 
ISTH = International Society on Thrombosis and Haemostasis; TIA = transient ischemic attack. 
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Figure 1. NAVIGATE ESUS design overview 
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Figure 2. Countries participating in NAVIGATE ESUS 
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Figure 3. Conceptual scheme for screening to identify ESUS patients. Prior to diagnostic 
testing, approximately 15% of strokes would be ESUS.  With each additional step in 
screening, the probability increases toward 100%.(5)   
*After excluding less uncommon stroke etiologies (e.g. dissections). 
 
 
 
